Quanta Dialysis Technologies Ltd, an Alcester, Warwickshire, UK-based medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, raised £38m ($48m) in a first closing of its Series C funding round.
The round was led by a Swiss private family office in combination with btov Partners and co-led by Wellington Partners and Seroba Life Sciences, along with participation from other existing investors.
The company intends to use the funds for the UK commercial launch of SC+ and a 510(k) submission to the FDA later this year.
Founded in 2008 and led by John E. Milad, Chief Executive Officer, Quanta is advancing SC+, a a small haemodialysis system designed to empower patients by giving them control over the delivery of their life-sustaining renal replacement therapy. The patented technology behind SC+ is based on a design innovation that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge.
As a CE marked medical device, SC+ has been piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional treatment regimens used in-centre.